EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF

Maximilian Trum iD, Johannes Riechel, Elisa Schollmeier, Simon Lebek iD, Philipp Hegner iD, Kathrin Reuthner, Silvia Heers, Karoline Keller, Michael Wester iD, Susanne Klatt, Nazha Hamdani iD, Zdenek Provaznik iD und 4 weitere

Cardiovascular Research · 31.07.2024 · 120 (9) · 999-1010

DOI: 10.1093/cvr/cvae095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 10.05.2024. Verfasst von Maximilian Trum und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Glucosides, Myocytes, Cardiac, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure. Die Arbeit wurde bisher 31-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Else Kröner-Fresenius-Stiftung, German Cardiac Society, DGK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Heart failure with preserved ejection fraction (HFpEF) causes substantial morbidity and mortality. Importantly, atrial remodelling and atrial fibrillation are frequently observed in HFpEF. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have recently been shown to improve clinical outcomes in HFpEF, and post-hoc analyses suggest atrial anti-arrhythmic effects. We tested if isolated human atrial cardiomyocytes from patients with HFpEF exhibit an increased Na influx, which is known to cause atrial arrhythmias, and if that is responsive to treatment with the SGTL2i empagliflozin. Methods and results Cardiomyocytes were isolated from atrial biopsies of 124 patients (82 with HFpEF) undergoing elective cardiac surgery. Na influx was measured with the Na-dye Asante Natrium Green–2 AM (ANG-2). Compared to patients without heart failure (NF), Na influx was doubled in HFpEF patients (NF vs. HFpEF: 0.21 ± 0.02 vs. 0.38 ± 0.04 mmol/L/min (N = 7 vs. 18); P = 0.0078). Moreover, late INa (measured via whole-cell patch clamp) was significantly increased in HFpEF compared to NF. Western blot and HDAC4 pulldown assay indicated a significant increase in CaMKII expression, CaMKII autophosphorylation, CaMKII activity, and CaMKII-dependent NaV1.5 phosphorylation in HFpEF compared to NF, whereas NaV1.5 protein and mRNA abundance remained unchanged. Consistently, increased Na influx was significantly reduced by treatment not only with the CaMKII inhibitor autocamtide-2-related inhibitory peptide (AIP), late INa inhibitor tetrodotoxin (TTX) but also with sodium/hydrogen exchanger 1 (NHE1) inhibitor cariporide. Importantly, empagliflozin abolished both increased Na influx and late INa in HFpEF. Multivariate linear regression analysis, adjusting for important clinical confounders, revealed HFpEF to be an independent predictor for changes in Na handling in atrial cardiomyocytes.

Conclusion

We show for the first time increased Na influx in human atrial cardiomyocytes from HFpEF patients, partly due to increased late INa and enhanced NHE1-mediated Na influx. Empagliflozin inhibits Na influx and late INa, which could contribute to anti-arrhythmic effects in patients with HFpEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesMyocytes, CardiacSodium-Glucose Transporter 2 InhibitorsHeart FailureBenzhydryl CompoundsStroke VolumeAction PotentialsHumansMaleFemaleAgedMiddle AgedSodiumHeart AtriaCalcium-Calmodulin-Dependent Protein Kinase Type 2Ventricular Function, LeftCells, CulturedAtrial Function, LeftSodium-Hydrogen Exchanger 1

Stichwörter der Autor:innen

Atrial remodellingEmpagliflozinHFpEFHeart failureSGLT2iSodium

Substanzen

GlucosidesempagliflozinSodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsSodiumCalcium-Calmodulin-Dependent Protein Kinase Type 2SLC9A1 protein, humanSodium-Hydrogen Exchanger 1

Autor:innen und Institutionen

  • Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
  • Department of Cellular and Translational Physiology, Ruhr-University Bochum, Bochum, Germany.
  • Department of Cardiothoracic Surgery, University Hospital Regensburg, Regensburg, Germany.

ORCID-Profile: Maximilian Trum, Simon Lebek, Philipp Hegner, Michael Wester, Nazha Hamdani, Zdenek Provaznik, Lars Maier, Stefan Wagner

Förderung

  • Else Kröner-Fresenius-Stiftung
  • German Cardiac Society
  • DGK
  • Deutsche Forschungsgemeinschaft
  • Philips Respironics
  • University of Regensburg ReForM A Program
  • ReForM C Program

Zitieren

APA

Trum, M., Riechel, J., Schollmeier, E., Lebek, S., Hegner, P., Reuthner, K., Heers, S., Keller, K., Wester, M., Klatt, S., Hamdani, N., Provaznik, Z., Schmid, C., Maier, L., Arzt, M., & Wagner, S. (2024). Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF. Cardiovascular Research, 120(9), 999-1010. https://doi.org/10.1093/cvr/cvae095

Vancouver

Trum M, Riechel J, Schollmeier E, Lebek S, Hegner P, Reuthner K, et al. Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF. Cardiovascular Research. 2024;120(9):999-1010. doi:10.1093/cvr/cvae095

BibTeX
@article{Trum2024,
  author = {Trum, Maximilian and Riechel, Johannes and Schollmeier, Elisa and Lebek, Simon and Hegner, Philipp and Reuthner, Kathrin and Heers, Silvia and Keller, Karoline and Wester, Michael and Klatt, Susanne and Hamdani, Nazha and Provaznik, Zdenek and Schmid, Christof and Maier, Lars and Arzt, Michael and Wagner, Stefan},
  title = {Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF},
  journal = {Cardiovascular Research},
  year = {2024},
  volume = {120},
  number = {9},
  pages = {999--1010},
  doi = {10.1093/cvr/cvae095}
}
Kostenlos starten →